Greenwich LifeSciences files patent claims to double GP2 market opportunity
Greenwich LifeSciences (NASDAQ:GLSI), a clinical-stage biopharmaceutical company focused on the development of GP2, an immunotherapy to prevent breast cancer recurrences, has filed new patent claims that could significantly expand the addressable market for its lead candidate, GLSI-100.










